Morgan Stanley Maintains Buy on Gilead Sciences (GILD)

​Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143.

​The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV pre-exposure prophylaxis. Flyn believes that this is a strong endorsement of the drug’s efficacy and safety. Moreover, the analyst also noted that the recommendation could lead to better patient adherence and stronger HIV prevention, thereby boosting the demand for Yeztugo.

​In addition, Gilead Sciences, Inc. (NASDAQ:GILD) is also working to secure commercial insurance coverage for Yeztugo and expects to have substantial coverage in place by the end of 2025.

​Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that develops medicines to treat serious diseases like HIV, viral hepatitis, COVID-19, and cancer.

While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.